Comparison of cervical cancer screening by self-sampling papillomavirus test versus pap-smear in underprivileged women in France.
Cervical cancer
Papillomavirus
SC-HPV
Screening
Vulnerability
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
26 05 2021
26 05 2021
Historique:
received:
16
04
2020
accepted:
12
05
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
1
6
2021
Statut:
epublish
Résumé
The purpose of this study was to compare cervical cancer screening by pap smear (PS) versus preliminary HPV testing based on self-collected samples (SC-HPV). Interventional study among underprivileged women from 25 to 65 years old in four French cities. The control group (CG) was referred for a PS. The experimental group (EG) conducted a SC-HPV test followed by a PS in case of positivity. Differences on screening completion and cytological abnormalities were analysed by logistic and Cox regression. 383 women were assigned to the EG and 304 to the CG. The screening completion proportion was 39.5% in the CG compared to 71.3% in the EG (HR = 2.48 (CI 95% [1.99-3.08]; p < 0.001). The proportion of cytological abnormalities was 2.0% in the CG and 2.3% in the EG (OR = 1.20 (CI 95% [0.42-3.40]; p = 0.7). The proportion of participants lost to follow-up was 60.5% in the CG and 63.2% in the EG HPV positive (p = 0.18). Providing an SC-HPV-test increased the participation of underprivileged women in CCS. Nevertheless, the significant number of lost to follow-up in both groups can undermine the initial benefits of the strategy for HPV positive women. Registration: Clinicaltrials.gov: NCT03118258.
Sections du résumé
BACKGROUND
The purpose of this study was to compare cervical cancer screening by pap smear (PS) versus preliminary HPV testing based on self-collected samples (SC-HPV).
METHODS
Interventional study among underprivileged women from 25 to 65 years old in four French cities. The control group (CG) was referred for a PS. The experimental group (EG) conducted a SC-HPV test followed by a PS in case of positivity. Differences on screening completion and cytological abnormalities were analysed by logistic and Cox regression.
RESULTS
383 women were assigned to the EG and 304 to the CG. The screening completion proportion was 39.5% in the CG compared to 71.3% in the EG (HR = 2.48 (CI 95% [1.99-3.08]; p < 0.001). The proportion of cytological abnormalities was 2.0% in the CG and 2.3% in the EG (OR = 1.20 (CI 95% [0.42-3.40]; p = 0.7). The proportion of participants lost to follow-up was 60.5% in the CG and 63.2% in the EG HPV positive (p = 0.18).
CONCLUSION
Providing an SC-HPV-test increased the participation of underprivileged women in CCS. Nevertheless, the significant number of lost to follow-up in both groups can undermine the initial benefits of the strategy for HPV positive women. Registration: Clinicaltrials.gov: NCT03118258.
Identifiants
pubmed: 34039341
doi: 10.1186/s12905-021-01356-8
pii: 10.1186/s12905-021-01356-8
pmc: PMC8157706
doi:
Banques de données
ClinicalTrials.gov
['NCT03118258']
Types de publication
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
221Références
BMJ. 2018 Dec 5;363:k4823
pubmed: 30518635
Eur J Public Health. 2010 Oct;20(5):555-63
pubmed: 20040522
Open AIDS J. 2013 Dec 30;7:58-66
pubmed: 24511334
J Fam Plann Reprod Health Care. 2012 Oct;38(4):229-38
pubmed: 22219504
BMC Public Health. 2014 Jun 12;14:596
pubmed: 24927941
Int J Womens Health. 2015 Nov 04;7:883-8
pubmed: 26604830
Int J Gynaecol Obstet. 2017 Mar;136(3):309-314
pubmed: 28099681
Lancet Oncol. 2014 Feb;15(2):172-83
pubmed: 24433684
Nat Rev Dis Primers. 2016 Dec 01;2:16086
pubmed: 27905473
BMC Womens Health. 2017 Mar 11;17(1):19
pubmed: 28284203
Front Oncol. 2014 Feb 20;4:31
pubmed: 24600587
Aust N Z J Public Health. 2001;25(1):55-61
pubmed: 11297304
J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23
pubmed: 19903804
Eur J Cancer Care (Engl). 2017 Jan;26(1):
pubmed: 26853214
Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):769-72
pubmed: 25713024
Cancer Med. 2015 Apr;4(4):620-31
pubmed: 25653188
J Med Screen. 2014 Dec;21(4):201-6
pubmed: 25312640
J Womens Health (Larchmt). 2016 Sep;25(9):944-51
pubmed: 26890012
Gynecol Oncol. 2014 Mar;132(3):636-42
pubmed: 24440471
Int J Cancer. 2013 Dec 1;133(11):2681-7
pubmed: 23712523
BMJ Open. 2017 Jun 11;7(6):e016282
pubmed: 28606908
Bull Cancer. 2009 Oct;96(10):961-9
pubmed: 19762324
Eur J Cancer. 2005 Nov;41(17):2704-8
pubmed: 16242316
Sex Transm Infect. 2006 Jun;82(3):260-2
pubmed: 16731682